Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed
- PMID: 11679973
- DOI: 10.1053/jhep.2001.28509
Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed
Abstract
We used a new real-time polymerase chain reaction (PCR)-based assay that is sensitive, has a wide dynamic linear range, and is highly reproducible to quantify hepatitis B virus (HBV) DNA in the serum of infected individuals undergoing potent antiviral therapy. In addition, we made frequent measurements of viral load after initiation of treatment and maintained follow-up to about 12 weeks. To analyze the data we used a new model of HBV decay, which takes into account that existing drug treatments do not completely block de novo infection and the possibility of noncytolytic loss of infected cells. On initiation of therapy, there was a mean delay of 1.6 days followed by a biphasic or muliphasic decay of plasma HBV DNA. The slope of the first phase varied considerably, with one individual having rapid decay, corresponding to a virion half-life of 1 hour, but others showing half-lives of up to 92 hours. Individuals either had a slow second-phase decline (t((1/2)) = 7.2 +/- 1.2 days) or a flat second phase. Some individuals exhibited a complex "staircase pattern" of decay, with further phases of viral DNA decline and phases with little change in viral load.
Similar articles
-
Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy.J Infect Dis. 2000 Feb;181(2):713-6. doi: 10.1086/315238. J Infect Dis. 2000. PMID: 10669360
-
Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B.Hepatology. 2000 Nov;32(5):1078-88. doi: 10.1053/jhep.2000.19619. Hepatology. 2000. PMID: 11050059
-
Sequential combination therapy of HBe antigen-negative/virus-DNA-positive chronic hepatitis B with famciclovir or lamivudine and interferon-alpha-2a.Liver Int. 2004 Apr;24(2):98-104. doi: 10.1111/j.1478-3231.2004.0889.x. Liver Int. 2004. PMID: 15078472 Clinical Trial.
-
Hepatitis B virus kinetics and mathematical modeling.Semin Liver Dis. 2004;24 Suppl 1:11-6. doi: 10.1055/s-2004-828673. Semin Liver Dis. 2004. PMID: 15192796 Review.
-
Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance.Am J Gastroenterol. 2002 Jul;97(7):1618-28. doi: 10.1111/j.1572-0241.2002.05819.x. Am J Gastroenterol. 2002. PMID: 12135009 Review.
Cited by
-
Hepatitis B virus translocates across a trophoblastic barrier.J Virol. 2007 Jul;81(13):7200-7. doi: 10.1128/JVI.02371-06. Epub 2007 Apr 18. J Virol. 2007. PMID: 17442714 Free PMC article.
-
Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?J Antimicrob Chemother. 2008 Jul;62(1):1-4. doi: 10.1093/jac/dkn175. Epub 2008 Apr 25. J Antimicrob Chemother. 2008. PMID: 18441341 Free PMC article. Review.
-
Understanding the antiviral effects of RNAi-based therapy in HBeAg-positive chronic hepatitis B infection.Sci Rep. 2021 Jan 8;11(1):200. doi: 10.1038/s41598-020-80594-6. Sci Rep. 2021. PMID: 33420293 Free PMC article.
-
Hepadnavirus Genome Replication and Persistence.Cold Spring Harb Perspect Med. 2015 Jul 1;5(7):a021386. doi: 10.1101/cshperspect.a021386. Cold Spring Harb Perspect Med. 2015. PMID: 26134841 Free PMC article. Review.
-
Development of mathematical models for the analysis of hepatitis delta virus viral dynamics.PLoS One. 2010 Sep 16;5(9):e12512. doi: 10.1371/journal.pone.0012512. PLoS One. 2010. PMID: 20862328 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical